Publications of Martin L. Sos
All genres
Journal Article (29)
2022
Journal Article
21 (5), pp. 821 - 830 (2022)
CD74-NRG1 fusions are oncogenic in vivo and induce therapeutically tractable ERBB2:ERBB3 heterodimerization. Molecular Cancer Therapeutics 2020
Journal Article
9 (14), pp. 4991 - 5007 (2020)
Sorafenib and everolimus in patients with advanced solid tumors and KRAS-mutated NSCLC: A phase I trial with early pharmacodynamic FDG-PET assessment. Cancer Medicine 2013
Journal Article
19 (9), pp. 2584 - 2591 (2013)
Characteristics of lung cancers harboring NRAS mutations. Clinical Cancer Research
Journal Article
5 (209), 209ra153 (2013)
A genomics-based classification of human lung tumors. Science Translational Medicine 2012
Journal Article
18 (17), pp. 4682 - 4690 (2012)
Differential protein stability and ALK inhibitor sensitivity of EML4-ALK fusion variants. Clinical Cancer Research
Journal Article
31 (20), pp. 3961 - 3975 (2012)
AATF/Che-1 acts as a phosphorylation-dependent molecular modulator to repress p53-driven apoptosis. EMBO Journal
Journal Article
44 (10), pp. 1104- - 11xx (2012)
Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nature Genetics
Journal Article
109 (42), pp. 17034 - 17039 (2012)
A framework for identification of actionable cancer genome dependencies in small cell lung cancer. Proceedings of the National Academy of Sciences of the United States of America
Journal Article
31 (46), pp. 4811 - 4814 (2012)
Genetic insight and therapeutic targets in squamous-cell lung cancer. Oncogene 2011
Journal Article
3 (90), p. 90ra59 - 90ra59 (2011)
Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling. Science Translational Medicine
Journal Article
1 (1), pp. 78 - 89 (2011)
Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discovery
Journal Article
17 (23), pp. 7394 - 7401 (2011)
ALK mutations conferring differential resistance to structurally diverse ALK inhibitors. Clinical Cancer Research
Journal Article
17 (11), pp. 1504 - 1508 (2011)
A crucial requirement for Hedgehog signaling in small cell lung cancer. Nature Medicine
Journal Article
19 (1), pp. 429 - 439 (2011)
Synthesis and biological evaluation of 7-substituted-1-(3-bromophenylamino)isoquinoline-4-carbonitriles as inhibitors of myosin light chain kinase and epidermal growth factor receptor. Bioorganic and Medicinal Chemistry
Journal Article
10, Art. 127 (2011)
L1CAM protein expression is associated with poor prognosis in non-small cell lung cancer. Molecular Cancer 2010
Journal Article
53 (7), pp. 2892 - 2901 (2010)
Synthesis and biological evaluation of 4-anilinoquinolines as potent inhibitors of epidermal growth factor receptor. Journal of Medicinal Chemistry
Journal Article
5 (1), p. e8919 - e8919 (2010)
Analysis of compound synergy in high-throughput cellular screens by population-based lifetime modeling. PLoS ONE
Journal Article
70 (3), pp. 868 - 874 (2010)
Chemogenomic profiling provides insights into the limited activity of irreversible EGFR inhibitors in tumor cells expressing the T790M EGFR resistance mutation. Cancer Research
Journal Article
2 (62), p. 62ra93 - 62ra93 (2010)
Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Science Translational Medicine 2009
Journal Article
8 (22), pp. 3652 - 3656 (2009)
Systematically linking drug susceptibility to cancer genome aberrations. Cell Cycle